ESMO Asia 2017: Osimertinib in Asian Patients With EGFR-Mutated Lung Cancer
In Asian patients with epidermal growth factor receptor (EGFR)-mutated advanced non–small cell lung cancer (NSCLC), first-line therapy with the third-generation EGFR tyrosine kinase inhibitor osimertinib has demonstrated superior efficacy over the standard of care (gefitinib or erlotinib) with a similar safety profile. These findings, presented by lead author Professor Byoung-Chul Cho, of the Yonsei Cancer Center, Seoul, Republic of Korea, at the European Society for Medical Oncology (ESMO) Asia 2017 Congress in Singapore (Abstract LBA6_PR) and simultaneously published in The New England Journal of Medicine, were consistent with the overall results of the phase III FLAURA study.
“Osimertinib should be the preferred first-line treatment for EGFR-mutant NSCLC in Asia,” declared Prof. Cho in an ESMO press release.
A total of 556 patients from Asia, Europe, and North America took part in the FLAURA trial. The subset analysis contained 322 Asian patients from this study.
The median progression-free survival with osimertinib was 16.5 months compared with 11.0 months with standard therapy, with a hazard ratio of 0.54. The median duration of response was twofold higher for those treated with osimertinib than for those treated with standard of care (17.6 vs. 8.7 months). The median overall survival has not been reached. No new safety findings were reported.